Successful treatment of childhood intramedullary spinal cord astrocytomas with irinotecan and cisplatin
Open Access
- 1 January 2007
- journal article
- case report
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 9 (1) , 39-46
Abstract
Childhood spinal cord astrocytomas are rare diseases, and their management is controversial. We report here our successful experience using irinotecan and cisplatin in three consecutive infants with progressing intramedullary astrocytomas. The first patient was a 16-month-old girl who presented with a grade III intramedullary astrocytoma that rapidly progressed after surgery and adjuvant chemotherapy. Weekly irinotecan (50 mg/m2) and cisplatin (30 mg/m2) for four consecutive weeks (one cycle) for a total of four cycles (I/C regimen) was used in order to avoid or delay radiotherapy. Radiological complete remission was achieved 10 months after completion of therapy, and 3.5 years after diagnosis the patient remains disease free. The second patient was a 19-month-old boy with a C3-T4 grade II intramedullary astrocytoma who received up-front vincristine and carboplatin for two months but remained clinically symptomatic. A followup MRI showed a larger tumor, and the patient was switched to the I/C regimen. A marked clinical improvement occurred after the first cycle, and MRI showed a very good partial remission at the end of therapy. At 16 months after diagnosis, the patient remains disease free. The third patient was a 10-month-old girl with a C2-T3 grade II intramedullary astrocytoma. She presented with severe pain that became steroid dependent during the month she was treated with the vincristine-carboplatin regimen. When she was switched to the I/C regimen, the clinical symptoms responded within days. MRI at the end of therapy showed a significant reduction in tumor size, and one year after diagnosis the patient remains symptom free. Using this I/C regimen for childhood intramedullary astrocytoma, we obtained remarkable clinicoradiological responses while avoiding the use of radiotherapy.Keywords
This publication has 46 references indexed in Scilit:
- A phase I study of irinotecan administered on a weekly schedule in pediatric patientsPediatric Blood & Cancer, 2005
- Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1?)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cellsJournal of Cancer Research and Clinical Oncology, 2004
- Intramedullary spinal cord astrocytomas in childrenPediatric Blood & Cancer, 2004
- Intramedullary spinal cord astrocytomas in childrenPediatric Blood & Cancer, 2004
- A Phase I Study of Irinotecan As a 3-Week Schedule in Children With Refractory or Recurrent Solid TumorsJournal of Clinical Oncology, 2003
- Phase II Study of Carboplatin in Children With Progressive Low-Grade GliomasJournal of Clinical Oncology, 2002
- Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: The Duke experienceNeuro-Oncology, 2002
- Carboplatin chemotherapy for progressive intramedullary spinal cord low-grade gliomas in children: Three case studies and a review of the literatureNeuro-Oncology, 2001
- Prognostic factors in intramedullary astrocytomasClinical Neurology and Neurosurgery, 1997
- Intramedullary ependymoma of the spinal cordJournal of Neurosurgery, 1990